Skip to main content

Peer Review reports

From: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial

Original Submission
4 Mar 2014 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
27 Mar 2014 Reviewed Reviewer Report - Erik Cobo
17 Apr 2014 Author responded Author comments - Nathan Hill
Resubmission - Version 3
17 Apr 2014 Submitted Manuscript version 3
22 Apr 2014 Editorially accepted
8 May 2014 Article published 10.1186/1745-6215-15-160

You can find further information about peer review here.

Back to article page